Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent ...

Full Year revenue of $314.0 million, recurring revenue growth of 47% YoYOn a constant currency basis revenue of $315.2 million, a 34% increase ...

Full Year revenue of $314.0 million, recurring revenue growth of 47% YoY On a constant currency basis revenue of $315.2 million, a 34% increase Adjusted EBITDA of $35.5 million (1) and Free Cash Flow ...